Matthew Rettig, MD
Enriched profileProfessor-in-Residence, Department of Medicine and Department of Urology, David Geffen School of Medicine at UCLA; Medical Director, Prostate Cancer Program, UCLA Institute of Urologic Oncology; Chief, Division of Hematology-Oncology, VA Greater Los Angeles Healthcare System · University of California, Los Angeles
Matthew Rettig is Professor-in-Residence, Department of Medicine and Department of Urology, David Geffen School of Medicine at UCLA; Medical Director, Prostate Cancer Program, UCLA Institute of Urologic Oncology; Chief, Division of Hematology-Oncology, VA Greater Los Angeles Healthcare System at University of California, Los Angeles. OpenAlex indexes 559 publications with 14,345 citations (h-index 61); ClinicalTrials.gov lists 12 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Matthew Rettig, MD, is Professor-in-Residence, Department of Medicine and Department of Urology, David Geffen School of Medicine at UCLA at University of California, Los Angeles (David Geffen School of Medicine). The public record shows 559 publications with 14,345 citations (h-index 61), centered on Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Radiopharmaceutical Chemistry and Applications. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 21 companies, 9 NIH-funded awards (2002–2025).
- Most recent indexed publication: 2026 · PloS one
- Top research focus: Prostate Cancer Treatment and Research
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 21 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 13 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 142.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Role of Race in Nutritional Approach in Men on ADT
Sponsor: University of California, Los Angeles
Industry payments
Updated 27 Aug 2026
21 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Bayer Healthcare Pharmaceuticals Inc.Program year202517 payments$27,592openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202527 payments$23,234openpaymentsdata.cms.gov ↗
- PROGENICS PHARMACEUTICALS, INC.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
91.4%Gonadotropin Releasing Hormone Receptor Agonist31.8%Leuprolide acetate100%Part B, office-administered≥46 patientsAnti-androgens26.6%Nubeqa69%Erleada31%Part D≥27 patientsMetabolism & gastrointestinal
5.1%Corticosteroid5.1%Prednisone100%Part D≥24 patientsGenitourinary & hormones
3.4%Progestin1.8%Megestrol Acetate100%Part D<11 patientsalpha-Adrenergic Blocker1.6%Tamsulosin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
9 NIH research awards on record, funded 2002–2025 per NIH RePORTER. The latest:
- Phase II Trial of targeted Radiation with no castration for mcrpc (POTENT-C)
Va Greater Los Angeles Healthcare System
FY2025I01CX002775 - A Phase 2 study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
Va Greater Los Angeles Healthcare System
FY2024I01CX002006 - Predicting Metastatic Progression of High Risk Localized Prostate Cancer
Va Greater Los Angeles Healthcare System
FY2024I01CX002622
Congress activity
Updated 27 Aug 2026
99 congress contributions (2008–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 7267: Genomic architecture of prostate cancer in <i>BRCA1/2</i> germline carriers
AACR Annual Meeting
AACR2026Co-author - Integration of genomic classification and clinical characteristics as a predictor of survival in de novo metastatic prostate cancer.
ASCO Annual Meeting
ASCO2026Co-author - Novel androgen receptor inhibitors for the treatment of metastatic castration-sensitive prostate cancer: A cost-effectiveness analysis.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
Clinical cancer research
Clinical Trial2024 - A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer.
Clinical cancer research
Clinical Trial2024
Most-cited works
by citation count (OpenAlex)- 01
- 02Assessment of <sup>68</sup>Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate CancerArticle794 citations2019
- 03Genomic Hallmarks and Structural Variation in Metastatic Prostate CancerArticle755 citations2018
- 04
- 05Size-selective collection of circulating tumor cells using Vortex technologyArticle496 citations2013
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/matthew-rettig-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/matthew-rettig-m-d-b808a2b4
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Matthew-Rettig-39967873
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
newsroom.ucla.edu/dept/faculty/matthew-rettig-recognized-va-prostate-cancer-research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →newsroom.ucla.edu ↗ - X / Twitter
x.com/PCFnews/status/1802019512058773595
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - X / Twitter
x.com/VAResearch/status/1787487792966029452
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Editorial & leadership roles
journal and society appointments- Chief
Division of Hematology-Oncology, VA Greater Los Angeles Healthcare System
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - Medical Director
Prostate Cancer Program, UCLA Institute of Urologic Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - National Co-Director
VA Precision Oncology Program for Cancer of the Prostate (POPCaP)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →newsroom.ucla.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- John B. Barnwell Award
VA Office of Clinical Science Research and Development (2024), for contributions to prostate cancer research; includes $150,000 in research support over three years
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →newsroom.ucla.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urotoday.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →guoncologynow.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urotoday.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregg Fonarow, MD
University of California, Los Angeles
Dennis Slamon, MD
University of California, Los Angeles
Tomas Ganz, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles